OPTIMISE: Optimisation of treatment selection and follow-up in oligometastatic colorectal cancer - a ctDNA-guided phase II randomised approach. Study protocol

Louise Bach Callesen; Torben Frøstrup Hansen; Rikke Fredslund Andersen; Niels Pallisgaard; Stine Kramer; Sven Schlander; Søren Rafael Rafaelsen; Anders Kindberg Boysen; Lars Henrik Jensen; Anders Jakobsen; Karen-Lise Garm Spindler

doi:10.1080/0284186X.2022.2116728

OPTIMISE: Optimisation of treatment selection and follow-up in oligometastatic colorectal cancer - a ctDNA-guided phase II randomised approach. Study protocol

Louise Bach Callesen^*, Torben Frøstrup Hansen, Rikke Fredslund Andersen, Niels Pallisgaard, Stine Kramer, Sven Schlander, Søren Rafael Rafaelsen, Anders Kindberg Boysen, Lars Henrik Jensen, Anders Jakobsen, Karen-Lise Garm Spindler

^*Corresponding author af dette arbejde

Patologiafdelingen

Publikation: Bidrag til tidsskrift › Letter › Forskning › peer review

Originalsprog	Engelsk
Sider (fra-til)	1152-1156
Antal sider	6
Tidsskrift	Acta Oncologica
Vol/bind	61
Udgave nummer	9
Tidlig onlinedato	12 sep. 2022
DOI	https://doi.org/10.1080/0284186X.2022.2116728
Status	Udgivet - sep. 2022

Adgang til dokumentet

10.1080/0284186X.2022.2116728

Citationsformater

Callesen, L. B., Hansen, T. F., Andersen, R. F., Pallisgaard, N., Kramer, S., Schlander, S., Rafaelsen, S. R., Boysen, A. K., Jensen, L. H., Jakobsen, A., & Spindler, K-L. G. (2022). OPTIMISE: Optimisation of treatment selection and follow-up in oligometastatic colorectal cancer - a ctDNA-guided phase II randomised approach. Study protocol. Acta Oncologica, 61(9), 1152-1156. https://doi.org/10.1080/0284186X.2022.2116728

@article{9e166696514a4c1fa3b06ff24b28c6a9,

title = "OPTIMISE: Optimisation of treatment selection and follow-up in oligometastatic colorectal cancer - a ctDNA-guided phase II randomised approach. Study protocol",

keywords = "Circulating Tumor DNA, Clinical Trials, Phase II as Topic, Colorectal Neoplasms/drug therapy, Follow-Up Studies, Humans, Patient Selection",

author = "Callesen, {Louise Bach} and Hansen, {Torben Fr{\o}strup} and Andersen, {Rikke Fredslund} and Niels Pallisgaard and Stine Kramer and Sven Schlander and Rafaelsen, {S{\o}ren Rafael} and Boysen, {Anders Kindberg} and Jensen, {Lars Henrik} and Anders Jakobsen and Spindler, {Karen-Lise Garm}",

year = "2022",

month = sep,

doi = "10.1080/0284186X.2022.2116728",

language = "English",

volume = "61",

pages = "1152--1156",

journal = "Acta Oncologica",

issn = "0284-186X",

publisher = "Informa Healthcare",

number = "9",

}

Callesen, LB, Hansen, TF, Andersen, RF, Pallisgaard, N, Kramer, S, Schlander, S, Rafaelsen, SR, Boysen, AK, Jensen, LH, Jakobsen, A & Spindler, K-LG 2022, 'OPTIMISE: Optimisation of treatment selection and follow-up in oligometastatic colorectal cancer - a ctDNA-guided phase II randomised approach. Study protocol', Acta Oncologica, bind 61, nr. 9, s. 1152-1156. https://doi.org/10.1080/0284186X.2022.2116728

OPTIMISE : Optimisation of treatment selection and follow-up in oligometastatic colorectal cancer - a ctDNA-guided phase II randomised approach. Study protocol. / Callesen, Louise Bach; Hansen, Torben Frøstrup; Andersen, Rikke Fredslund et al.

I: Acta Oncologica, Bind 61, Nr. 9, 09.2022, s. 1152-1156.

Publikation: Bidrag til tidsskrift › Letter › Forskning › peer review

TY - JOUR

T1 - OPTIMISE

T2 - Optimisation of treatment selection and follow-up in oligometastatic colorectal cancer - a ctDNA-guided phase II randomised approach. Study protocol

AU - Callesen, Louise Bach

AU - Hansen, Torben Frøstrup

AU - Andersen, Rikke Fredslund

AU - Pallisgaard, Niels

AU - Kramer, Stine

AU - Schlander, Sven

AU - Rafaelsen, Søren Rafael

AU - Boysen, Anders Kindberg

AU - Jensen, Lars Henrik

AU - Jakobsen, Anders

AU - Spindler, Karen-Lise Garm

PY - 2022/9

Y1 - 2022/9

KW - Circulating Tumor DNA

KW - Clinical Trials, Phase II as Topic

KW - Colorectal Neoplasms/drug therapy

KW - Follow-Up Studies

KW - Humans

KW - Patient Selection

U2 - 10.1080/0284186X.2022.2116728

DO - 10.1080/0284186X.2022.2116728

M3 - Letter

C2 - 36094310

VL - 61

SP - 1152

EP - 1156

JO - Acta Oncologica

JF - Acta Oncologica

SN - 0284-186X

IS - 9

ER -